Loading patent…
AssigneeFlagship Pioneering Innovations V, Inc.
InventorsAnthony Michael Barsotti, Alexandra Masu Cantley, Jason Park, Douglas Gowers Cole
Estimating the term…
In one aspect, the invention provides methods of increasing immune response by administering postcellular signaling factors produced by cells exposed to a stress condition. In one aspect, the invention provides methods of increasing immune response by administering in combination (a) a Stimulator of Interferon Genes (STING) agonist and (b) a purinergic receptor agonist. The increase in immune response may be used, for example, for treatment of infection or cancer. The invention also provides screening assays for identification of compounds that induce production of postcellular signaling factors which are also immunostimulatory agents. The invention further provides methods for identifying postcellular signaling factors with immunostimulatory activity. In another aspect, the invention provides methods of decreasing immune response by administering to a cell, tissue or subject a purinergic receptor antagonist alone or in combination with a Stimulator of Interferon Genes (STING) antagonist.
A method of treating a cancer in a subject, comprising administering to the subject, in combination (a) a Stimulator of Interferon Genes (STING) agonist, wherein the STING agonist is a cyclic dinucleotide, and (b) a P2Y2 receptor agonist compound selected from:
A method of treating a cancer in a subject, comprising administering to the subject, in combination (a) a Stimulator of Interferon Genes (STING) agonist, wherein the STING agonist is ADU-S100 or MK-1454, and (b) a P2Y2 receptor agonist, wherein the P2Y2 receptor agonist is diquafosol, denufosol, Ap4A, or a pharmaceutically acceptable salt thereof, wherein a response of the cancer to treatment is improved relative to a treatment with the STING agonist alone.
Dependencies are inferred from the claim text.